Get the Stockscreener App
36.26
2.60%
0.92
After Hours:
36.26
Biohaven Ltd stock is traded at $36.26, with a volume of 2.75M.
It is up +2.60% in the last 24 hours and down -22.57% over the past month.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
See More
Previous Close:
$35.34
Open:
$34.85
24h Volume:
2.75M
Relative Volume:
2.57
Market Cap:
$3.67B
Revenue:
-
Net Income/Loss:
$-804.34M
P/E Ratio:
-4.8541
EPS:
-7.47
Net Cash Flow:
$-531.06M
1W Performance:
-5.74%
1M Performance:
-22.57%
6M Performance:
+8.43%
1Y Performance:
-4.38%
1-Day Range:
$34.46
$36.95
1-Week Range:
$34.46
$42.13
52-Week Range:
$26.80
$62.21
Biohaven Ltd Stock (BHVN) Company Profile
Name
Biohaven Ltd
Sector
Industry
Phone
203-404-0410
Address
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
36.26 | 3.67B | 0 | -804.34M | -531.06M | -9.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-16-24 | Initiated | Jefferies | Buy |
| Sep-04-24 | Initiated | Bernstein | Outperform |
| Jul-24-24 | Initiated | Morgan Stanley | Overweight |
| Feb-16-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Dec-22-23 | Initiated | H.C. Wainwright | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Jan-24-23 | Initiated | SVB Securities | Outperform |
| Jan-04-23 | Initiated | JP Morgan | Overweight |
| Dec-02-22 | Initiated | BTIG Research | Buy |
| Oct-26-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-12-22 | Initiated | Piper Sandler | Overweight |
| Aug-19-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-08-22 | Downgrade | Wedbush | Outperform → Neutral |
| May-11-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-21 | Downgrade | UBS | Buy → Neutral |
| Aug-03-21 | Reiterated | Canaccord Genuity | Buy |
| Mar-11-21 | Initiated | UBS | Buy |
| Dec-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-17-20 | Initiated | Cowen | Outperform |
| Feb-10-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Nov-22-19 | Initiated | Wedbush | Outperform |
| Jun-25-19 | Reiterated | Canaccord Genuity | Buy |
| May-06-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-19 | Reiterated | Needham | Buy |
| Jul-03-18 | Reiterated | Needham | Buy |
| Jul-02-18 | Reiterated | Needham | Buy |
| Apr-05-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-22-18 | Reiterated | Canaccord Genuity | Buy |
| Dec-15-17 | Initiated | Canaccord Genuity | Buy |
| Oct-03-17 | Reiterated | Needham | Buy |
View All
Biohaven Ltd Stock (BHVN) Latest News
Geode Capital Management LLC Buys 44,174 Shares of Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven (NYSE:BHVN) Stock Price Down 6.1%What's Next? - MarketBeat
Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval - AOL
Bernstein reiterates Outperform rating on Biohaven stock, sees strong upside potential - Investing.com Australia
Biohaven's (BHVN) Overweight Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Biohaven (NYSE:BHVN) Given Buy Rating at HC Wainwright - MarketBeat
Is Biohaven Ltd. (BHVN) the Best Weight Loss Stock to Buy Now According to Hedge Funds? - Insider Monkey
Biohaven (NYSE:BHVN) Shares Gap DownWhat's Next? - MarketBeat
Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates - PR Newswire
Biohaven Ltd. (NYSE:BHVN) Holdings Boosted by Barclays PLC - MarketBeat
Wellington Management Group LLP Boosts Stock Holdings in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven's SWOT analysis: neurological drug developer's stock poised for growth - Investing.com
12 Best Weight Loss Stocks to Buy According to Hedge Funds - Insider Monkey
State Street Corp Sells 393,278 Shares of Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven Announces Proposed Public Offering of Common Shares - The Eastern Progress Online
Learn to Evaluate (BHVN) using the Charts - Stock Traders Daily
Y Intercept Hong Kong Ltd Acquires Shares of 26,789 Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven Announces Pricing of $250 Million Public Offering of Common Shares - The Eastern Progress Online
Biohaven Ltd. (NYSE:BHVN) Shares Acquired by XTX Topco Ltd - MarketBeat
Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine - The Eastern Progress Online
Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Rel - GuruFocus.com
Biohaven Pharma (BHVN) Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates - StreetInsider.com
Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting – Company AnnouncementFT.com - Financial Times
Fmr LLC Sells 13,092 Shares of Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Stifel Financial Corp Purchases 28,684 Shares of Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven Ltd. (NYSE:BHVN) Shares Sold by Redmile Group LLC - MarketBeat
Point72 Asset Management L.P. Has $74.97 Million Stock Position in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven Ltd. (NYSE:BHVN) Stock Position Raised by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Biohaven shares target increased, rating held on FDA catalyst potential By Investing.com - Investing.com Australia
Charles Schwab Investment Management Inc. Has $31.62 Million Stock Position in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Janus Henderson Group PLC Boosts Stock Position in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Holocene Advisors LP Lowers Stock Position in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Erste Asset Management GmbH Invests $2.62 Million in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Analysts Set Biohaven Ltd. (NYSE:BHVN) Price Target at $62.75 - MarketBeat
Trading (BHVN) With Integrated Risk Controls - Stock Traders Daily
Fred Alger Management LLC Grows Position in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
D.A. Davidson & CO. Makes New $1.20 Million Investment in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Intech Investment Management LLC Acquires New Stake in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Citigroup Inc. Has $5.99 Million Position in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven Ltd. (NYSE:BHVN) Shares Sold by Eventide Asset Management LLC - MarketBeat
Biohaven's Revenue Path: SCA And Obesity Therapies (NYSE:BHVN) - Seeking Alpha
Algert Global LLC Acquires 24,990 Shares of Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven’s Phase III SMA miss: was it the target or the trial design? - BioCentury
Biohaven's (BHVN) Buy Rating Reiterated at HC Wainwright - MarketBeat
Scholar Rock shares surge 26% as rival Biohaven misses SMA study goal - TradingPedia
Biohaven’s myostatin inhibitor fails in phase 3 spinal muscular atrophy trial - BioPharma-Reporter.com
Biohaven's spinal muscular atrophy drug fails to meet study goal - Reuters
Biohaven shares retains overweight rating on clinical trial By Investing.com - Investing.com South Africa
Biohaven shares retain Outperform rating as Baird highlights optimism for obesity Phase 2 trial By Investing.com - Investing.com South Africa
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study - Benzinga
Biohaven muscle drug misses goal of SMA study, but advances in obesity - BioPharma Dive
Biohaven Ltd Stock (BHVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):